With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

USA News Group News Commentary
Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, June 20, 2025 /CNW/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Immuneering Corporation (NASDAQ:IMRX), GRAIL, Inc. (NASDAQ:GRAL), Intensity Therapeutics, Inc. (NASDAQ:INTS), and Relay Therapeutics, Inc. (NASDAQ:RLAY).